Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Delivering TB vaccine intravenously dramatically improves potency, study shows

02.01.2020

Worldwide, more people die from tuberculosis (TB) than any other infectious disease, even though the vast majority were vaccinated. The vaccine just isn't that reliable. But a new Nature study finds that simply changing the way the vaccine is administered could dramatically boost its protective power.

Researchers at the University of Pittsburgh School of Medicine and the National Institute of Allergy and Infectious Diseases (NIAID) discovered that intravenous TB vaccination is highly protective against the infection in monkeys, compared to the standard injection directly into the skin, which offers minimal protection.


3D PET CT scans of monkey lungs showing inflammation (red and yellow) from TB infection. The top row were vaccinated the usual way with a shot into the skin The bottom row received the vaccine intravenously.

Credit: JoAnne Flynn, Ph.D., Alexander White, Pauline Maiello, and Mario Roederer, Ph.D.

"The effects are amazing," said senior author JoAnne Flynn, Ph.D., professor of microbiology and molecular genetics at the Pitt Center for Vaccine Research. "When we compared the lungs of animals given the vaccine intravenously versus the standard route, we saw a 100,000-fold reduction in bacterial burden. Nine out of 10 animals showed no inflammation in their lungs."

Flynn's team tested several routes and doses of the only commercially available human TB vaccine, Bacille Calmette-Guérin (BCG), which is made of a live, weakened form of TB bacteria found in cattle.

... more about:
»NIAID »T cells »TB »TB bacteria »TB vaccine »lungs

The BCG vaccine has been around for 100 years and is among the most widely used vaccines in the world, but its efficacy varies widely.

The idea for an intravenous TB vaccination came from earlier experiments by the other senior author on the study, Robert Seder, M.D., at the NIAID's Vaccine Research Center. Seder showed in both animals and humans that the malaria vaccine is more effective when delivered intravenously.

To test whether the method of administration matters for TB, Flynn and colleagues separated their colony of monkeys into six groups: unvaccinated, standard human injection, stronger dose but same injection route, mist, injection plus mist, and finally, the stronger dose of BCG delivered as a single shot directly into the vein.

Six months later, the researchers exposed the animals to TB and monitored them for signs of infection.

Monkeys are extremely susceptible to TB. All of the animals who received the standard human dose had persistent lung inflammation, and the average amount of TB bacteria in their lungs was only slightly less than in the monkeys who received no vaccine at all. The other injected and inhaled vaccines offered similarly modest TB protection.

The intravenous vaccine, on the other hand, offered nearly full protection. There was virtually no TB bacteria in the lungs of these animals, and only one monkey in this group developed lung inflammation.

"The reason the intravenous route is so effective," Flynn explained, "is that the vaccine travels quickly through the bloodstream to the lungs, the lymph nodes and the spleen, and it primes the T cells before it gets killed."

Flynn's team found BCG and activated T cells in the lungs of all the intravenously vaccinated animals. Among the other groups, BCG was undetectable in the lung tissue and T cell responses were relatively meagre.

Next, the researchers plan to test whether lower doses of intravenous BCG could offer the same level of protection without the side effects, which mostly consist of temporary inflammation in the lungs.

But before this method can be translated to humans, researchers need to know that it's not only safe, but also practical. An intravenous vaccine requires more skill to administer and carries a higher risk of infection.

"We're a long way from realizing the translational potential of this work," Flynn said. "But eventually we do hope to test in humans."

###

Additional authors on the study include Patricia Darrah, Ph.D., Joshua Hackney, Supriya Pokkali, Ph.D., Phillip Swanson, M.D., Megha Kamath, and Mario Roederer, Ph.D., of NIAID; Joseph Zeppa, Ph.D., Pauline Maiello, Nicole Grant, Mark Rodgers, M.S., Chelsea Causgrove, Edwin Klein, D.V.M., Alexander White, and Charles Scanga, Ph.D., of Pitt; Marc Wadsworth, Travis Hughes, M.P.H., and Alex Shalek, Ph.D., of the Massachusetts Institute of Technology and Harvard University; Dominick Laddy, Ph.D., and Danilo Casimiro, Ph.D., of Aeras; Aurelio Bonavia, Ph.D., of Vir Biotechnology; and Philana Ling Lin, M.D., of UPMC Children's Hospital of Pittsburgh.

This research was supported by the Bill and Melinda Gates Foundation, the National Institutes of Health (grants 5U24AI118672 and 2RM1HG006193) and the NIAID Intramural Research Program. PARI Pharma GbmH provided the aerosol vaccine delivery device.

To read this release online or share it, visit https://www.upmc.com/media/news/010120-bcg-iv-vaccine [when embargo lifts].

About the University of Pittsburgh School of Medicine

As one of the nation's leading academic centers for biomedical research, the University of Pittsburgh School of Medicine integrates advanced technology with basic science across a broad range of disciplines in a continuous quest to harness the power of new knowledge and improve the human condition. Driven mainly by the School of Medicine and its affiliates, Pitt has ranked among the top 10 recipients of funding from the National Institutes of Health since 1998. In rankings recently released by the National Science Foundation, Pitt ranked fifth among all American universities in total federal science and engineering research and development support.

Likewise, the School of Medicine is equally committed to advancing the quality and strength of its medical and graduate education programs, for which it is recognized as an innovative leader, and to training highly skilled, compassionate clinicians and creative scientists well-equipped to engage in world-class research. The School of Medicine is the academic partner of UPMC, which has collaborated with the University to raise the standard of medical excellence in Pittsburgh and to position health care as a driving force behind the region's economy. For more information about the School of Medicine, see http://www.medschool.pitt.edu.

http://www.upmc.com/media

Contact: Erin Hare
Office: 412-864-7194
Mobile: 412-738-1097
E-mail: HareE@upmc.edu

Contact: Allison Hydzik
Office: 412-647-9975
Mobile: 412-559-2431
E-mail: HydzikAM@upmc.edu

http://www.pitt.edu 

Erin Hare | EurekAlert!
Further information:
http://dx.doi.org/10.1038/s41586-019-1817-8

Further reports about: NIAID T cells TB TB bacteria TB vaccine lungs

More articles from Health and Medicine:

nachricht Scientists examine how a gut infection may produce chronic symptoms
13.01.2020 | Rockefeller University

nachricht Deep learning, 3D technology to improve structure modeling, create better drugs
10.01.2020 | Purdue University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: World Premiere in Zurich: Machine keeps human livers alive for one week outside of the body

Researchers from the University Hospital Zurich, ETH Zurich, Wyss Zurich and the University of Zurich have developed a machine that repairs injured human livers and keep them alive outside the body for one week. This breakthrough may increase the number of available organs for transplantation saving many lives of patients with severe liver diseases or cancer.

Until now, livers could be stored safely outside the body for only a few hours. With the novel perfusion technology, livers - and even injured livers - can now...

Im Focus: SuperTIGER on its second prowl -- 130,000 feet above Antarctica

A balloon-borne scientific instrument designed to study the origin of cosmic rays is taking its second turn high above the continent of Antarctica three and a half weeks after its launch.

SuperTIGER (Super Trans-Iron Galactic Element Recorder) is designed to measure the rare, heavy elements in cosmic rays that hold clues about their origins...

Im Focus: LZH’s MOMA laser ready for the flight to Mars

One last time on Earth it has been turned on in France in December 2019. The next time the MOMA laser developed by the Laser Zentrum Hannover e.V. (LZH) is going into operation will be on Mars. The ExoMars rover into which the laser is integrated has now successfully passed the thermal vacuum tests at Airbus in Toulouse, France.

For 18 days the ExoMars rover Rosalind Franklin was subjected to thermal vacuum tests at Airbus. There, it had to withstand strong changes in temperature and...

Im Focus: Atacama Desert: A newly discovered biocoenosis of lichens, fungi and algae shapes entire landscapes

The Atacama Desert in Chile is the oldest and most arid desert on earth. Organisms living in this area have adapted to the extreme conditions over thousands of years. A research team led by Dr Patrick Jung has now discovered and investigated a previously unknown biocoenosis of lichens, fungi, cyanobacteria and algae. It colonises tiny stones, so-called grit and its need for water is satisfied by fog and dew. These organisms also decompose the rock on and in which they live. The scientists believe that this is how they have shaped the landscape of the Atacama Desert. Their study was published in the renowned scientific journal "Gebiology".

Many desert areas have large black spots in the sand. These spots are mineral deposits, so-called desert varnish. In the Atacama Desert, which can be compared...

Im Focus: Nano antennas for data transfer

For the first time, physicists from the University of Würzburg have successfully converted electrical signals into photons and radiated them in specific directions using a low-footprint optical antenna that is only 800 nanometres in size.

Directional antennas convert electrical signals to radio waves and emit them in a particular direction, allowing increased performance and reduced...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

„Advanced Battery Power“- Conference, Contributions are welcome!

07.01.2020 | Event News

International Coral Reef Symposium 2020 Holds Photo Competition

19.12.2019 | Event News

The Future of Work

03.12.2019 | Event News

 
Latest News

Scientists in Mainz develop a more sustainable photochemistry

14.01.2020 | Life Sciences

Laserphysics: At the pulse of a light wave

13.01.2020 | Physics and Astronomy

New function for potential tumor suppressor in brain development

13.01.2020 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>